Table 2.
Comparison of characteristics between RASP patients and non‐RASP patients
| Characteristics | RASP patients (N = 81) | Non‐RASP patients (N = 133) | P value |
|---|---|---|---|
| Age (y) | 60.1 ± 8.7 | 58.2 ± 8.8 | 0.129 |
| Gender (male/female) | 61/20 | 110/23 | 0.190 |
| BMI (kg/m2) | 26.3 ± 3.1 | 25.6 ± 3.0 | 0.107 |
| Smoke (n/%) | 30 (37.0) | 46 (34.6) | 0.716 |
| Hypertension (n/%) | 64 (79.0) | 97 (72.9) | 0.318 |
| DM (n/%) | 29 (35.8) | 30 (22.6) | 0.035 |
| Hypercholesteremia (n/%) | 54 (66.7) | 73 (54.9) | 0.089 |
| Hyperuricemia (n/%) | 33 (40.7) | 58 (43.6) | 0.681 |
| Family history of CAD (n/%) | 16 (19.8) | 23 (17.3) | 0.651 |
| LVEF (%) | 65.06 ± 5.8 | 64.93 ± 7.0 | 0.876 |
| Laboratory tests | |||
| MAP (mm Hg) | 103.68 ± 17.45 | 104.61 ± 17.58 | 0.707 |
| FBG (mmol/L) | 5.75 (5.28‐6.60) | 5.70 (5.02‐6.52) | 0.534 |
| Glycated hemoglobin (%) | 6.34 ± 1.75 | 6.20 ± 1.93 | 0.575 |
| Scr (μmol/L) | 79.17 ± 16.94 | 81.76 ± 16.55 | 0.272 |
| SUA (μmol/L) | 357.10 ± 73.46 | 325.56 ± 85.56 | 0.006 |
| cTnI (ng/mL) | 0.033 (0.024‐0.043) | 0.027 (0.014‐0.039) | 0.022 |
| NT‐proBNP (ng/mL) | 0.088 (0.053‐0.120) | 0.066 (0.036‐0.108) | 0.026 |
| TG (mmol/L) | 1.83 (1.07‐2.53) | 1.68 (0.99‐2.41) | 0.244 |
| TC (mmol/L) | 4.55 ± 1.03 | 4.71 ± 0.97 | 0.240 |
| LDL‐C (mmol/L) | 2.79 ± 0.60 | 2.80 ± 0.61 | 0.901 |
| HDL‐C (mmol/L) | 0.99 ± 0.28 | 1.05 ± 0.26 | 0.100 |
| Hs‐CRP (mg/L) | 3.12 (1.05‐6.10) | 1.88 (0.93‐3.19) | 0.001 |
| ESR (mm/L) | 7.35 ± 4.23 | 6.69 ± 3.71 | 0.235 |
| WBC (109/L) | 6.13 ± 1.39 | 5.98 ± 1.52 | 0.486 |
| Neutrophil (109/L) | 3.62 ± 1.02 | 3.38 ± 0.99 | 0.098 |
| Coronary angiography findings | |||
| Multivessel artery lesions (n/%) | 71 (87.7) | 89 (66.9) | 0.001 |
| Target lesion at LAD (n/%) | 42 (51.9) | 78 (58.6) | 0.331 |
| Target lesion at LCX (n/%) | 25 (30.9) | 55 (41.4) | 0.124 |
| Target lesion at RCA (n/%) | 33 (40.7) | 42 (31.6) | 0.173 |
| Patients with two target lesions (n/%) | 19 (23.5) | 42 (31.6) | 0.202 |
| Stenosis degree of target lesion (%) | 87.00 (84.00‐92.00) | 88.00 (85.00‐92.00) | 0.643 |
| Length of target lesion (mm) | 36.00 (28.50‐43.00) | 34.00 (27.00‐39.50) | 0.113 |
| PCI surgery parameters | |||
| Bifurcation requiring double wiring (n/%) | 39 (48.1) | 34 (25.6) | 0.001 |
| Length of stent (mm) | 39.00 (32.00‐47.00) | 37.00 (31.00‐43.00) | 0.123 |
| Diameter of stent (mm) | 3.30 (3.00‐3.40) | 3.20 (3.00‐3.40) | 0.223 |
| Time of stent dilation (s) | 15.00 (12.00‐18.00) | 16.00 (13.00‐18.00) | 0.286 |
| Balloon dilation pre‐stent (n/%) | 26 (32.1) | 43 (32.3) | 0.972 |
| Drugs used after surgery | |||
| Aspirin (n/%) | 81 (100.0) | 133 (100.00) | ‐ |
| Nitrates (n/%) | 78 (96.3) | 127 (95.5) | 0.775 |
| Statins (n/%) | 79 (97.5) | 129 (97.0) | 0.817 |
| β‐receptor blockers (n/%) | 73 (90.1) | 123 (92.5) | 0.547 |
| ACEIs/ARBs (n/%) | 57 (70.4) | 93 (69.9) | 0.945 |
| Calcium channel blockers (n/%) | 27 (33.3) | 48 (36.1) | 0.682 |
RASP, rapid angiographic stenotic progression; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; FBG, fasting blood‐glucose; Scr, serum creatinine; SUA, serum uric acid; cTnI, cardiac troponin I; NT‐proBNP, N‐terminal probrain natriuretic peptide; TG, triglyceride; TC, total cholesterol; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; Hs‐CRP, high‐sensitivity C‐reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; ACEIs/ARBs, angiotensin converting enzymes inhibitors/angiotensin receptor blockers.
Data were presented as mean value ± standard deviation, median (25th‐75th quantiles), or count (percentage). Comparison between two groups was determined by t test, Wilcoxon rank sum test, or chi‐square test. P value <0.05 was considered significant. Statistically significant values were shown in bold font.